Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06515262 | Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | recruiting | N/A | 10 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06111612 | Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement | recruiting | — | 50 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
| 1 |
| Jul 22, 2024 |
| clinicaltrials |
| NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | recruiting | Phase 2 | 39 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06513234 | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | recruiting | Phase 2 | 45 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05504772 | Precision Medicine for Every Child With Cancer(ZERO2) | recruiting | — | 3,500 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jul 17, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05159245 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE) | recruiting | Phase 2 | 250 | Helsinki University Central HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | recruiting | Phase 3 | 78 | Ruijin HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06301425 | MRD Response-adapted Allo-HSCT for Adverse-risk AML | recruiting | N/A | 178 | Peking University People's HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | recruiting | Phase 1 | 32 | Ruijin HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05636787 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients(TreoMel) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06430736 | PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)(PRONTO) | recruiting | Phase 2 | 100 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05870475 | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV(PV) | recruiting | Phase 2 | 94 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06482684 | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma(CARMAN) | recruiting | Phase 2 | 150 | Christian Schmidt, MDOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05029531 | Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021) | recruiting | Phase 3 | 80 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06477549 | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT05772559 | Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies(ALARM3) | recruiting | — | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06466889 | Mastocytosis Registry (of Zurich)(MastoR) | recruiting | — | 400 | University of ZurichOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06475469 | Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk | recruiting | N/A | 75 | CHU de ReimsOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06463717 | Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not | recruiting | — | 210 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 24, 2024 | clinicaltrials |
| NCT06454968 | Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma. | recruiting | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06462248 | Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies | recruiting | Phase 2 | 20 | Chi Kong LiOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06462664 | Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM)(EMYNEM) | recruiting | — | 10 | University Hospital, BrestOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT03832127 | Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients(Myelofludate) | recruiting | Phase 1 | 35 | Nantes University HospitalOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05811845 | Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALL | recruiting | — | 250 | IRCCS Burlo GarofoloOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06461182 | Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma(PentixaFor) | recruiting | Phase 2 | 15 | Koo Foundation Sun Yat-Sen Cancer CenterOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06407947 | Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma | recruiting | Early Phase 1 | 10 | Shanghai Changzheng HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT06445803 | CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL | recruiting | Phase 1 | 48 | Rong TaoOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05248633 | Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma | recruiting | Phase 2 | 220 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06439173 | Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment | recruiting | — | 40 | Instituto de Investigación Biomédica de SalamancaOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06440148 | Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis | recruiting | — | 50 | Medical University of LublinOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT06436677 | A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma(AMITY) | recruiting | — | 100 | Peking University First HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT04905810 | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | recruiting | Phase 2 | 20 | Brian JonasOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence(CAPTiRALL) | recruiting | Phase 1 / Phase 2 | 26 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05326919 | The Patient Cohort of the National Center for Precision Medicine in Leukemia(eTHEMA) | recruiting | — | 3,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05580861 | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment(SALMA) | recruiting | Phase 1 / Phase 2 | 64 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05868395 | Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06225128 | Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia(DREAM) | recruiting | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06299553 | Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | recruiting | — | 200 | Incyte Biosciences Italy S.r.lINDUSTRY | 1 | May 22, 2024 | clinicaltrials |
| NCT06421805 | Establishing Prospective Mediastinal Tumor Database of PUMCH(MTDPUMCH) | recruiting | — | 2,000 | Peking Union Medical College HospitalOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05439889 | Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission | recruiting | — | 100 | National Taiwan University HospitalOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06418776 | IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML | recruiting | Phase 3 | 198 | National Research Center for Hematology, RussiaNETWORK | 1 | May 17, 2024 | clinicaltrials |
| NCT06410833 | Belimumab After Rituximab in Resistant Primary Juvenile SS(BRRPJS) | recruiting | Phase 4 | 15 | Peking Union Medical College HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06416761 | Genetics in the Progression of Nephropathies | recruiting | — | 10,000 | Ospedale San RaffaeleOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06346912 | CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL | recruiting | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04061512 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia(RAINBOW) | recruiting | Phase 2 / Phase 3 | 148 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05950997 | A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL | recruiting | N/A | 89 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06002659 | CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)(CARMA-01) | recruiting | Phase 1 / Phase 2 | 18 | Uppsala UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05502887 | The Endothelial Cell Dysfunction and Outcome Project for Hematological Neoplasms(EndoCDO-H) | recruiting | — | 1,000 | Prof. Dr. Thomas LuftOTHER | 1 | May 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2024source: clinicaltrials